scPharmaceuticals Inc (NASDAQ:SCPH)’s traded shares stood at 0.62 million during the last session, with the company’s beta value hitting 0.28. At the close of trading, the stock’s price was $2.32, to imply an increase of 15.14% or $0.3 in intraday trading. The SCPH share’s 52-week high remains $5.65, putting it -143.53% down since that peak but still an impressive 16.38% since price per share fell to its 52-week low of $1.94. The company has a valuation of $116.66M, with an average of 0.66 million shares in intraday trading volume over the past 10 days and average of 446.06K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for scPharmaceuticals Inc (SCPH), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give SCPH a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.28.
scPharmaceuticals Inc (NASDAQ:SCPH) trade information
After registering a 15.14% upside in the last session, scPharmaceuticals Inc (SCPH) has traded red over the past five days. The 5-day price performance for the stock is 0.00%, and -22.41% over 30 days. With these gigs, the year-to-date price performance is -34.46%. Short interest in scPharmaceuticals Inc (NASDAQ:SCPH) saw shorts transact 5.67 million shares and set a 9.55 days time to cover.
The extremes give us $13 and $13 for target low and target high price respectively. As such, SCPH has been trading -460.34% off suggested target high and -460.34% from its likely low.
scPharmaceuticals Inc (SCPH) estimates and forecasts
The rating firms project that company’s revenue will grow 109.80% compared to the previous financial year.
Revenue forecast for the current quarter as set by 5 analysts is 11.63M. Meanwhile, for the current quarter, a total of 5 analyst(s) estimate revenue growth to 16.43M.Earnings reports from the last fiscal year show that sales brought in 6.1M and 8.05M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 90.57% before jumping 104.04% in the following quarter.
SCPH Dividends
scPharmaceuticals Inc has its next earnings report out on 2025-Mar-18. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
scPharmaceuticals Inc (NASDAQ:SCPH)’s Major holders
scPharmaceuticals Inc insiders hold 11.16% of total outstanding shares, with institutional holders owning 84.89% of the shares at 95.56% float percentage. In total, 84.89% institutions holds shares in the company, led by ORBIMED ADVISORS LLC. As of 2024-06-30, the company held over 5.56 million shares (or 14.2608% of shares), all amounting to roughly $24.18 million.
The next major institution holding the largest number of shares is RUBRIC CAPITAL MANAGEMENT LP with 3.52 million shares, or about 9.042% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $15.33 million.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the scPharmaceuticals Inc (SCPH) shares. Going by data provided on Dec 31, 2024 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 1.14 shares. This is just over 2.26% of the total shares, with a market valuation of $2.64 million. Data from the same date shows that the other fund manager holds a little less at 854.33, or 1.70% of the shares, all valued at about 1.98 million.
